Chimerix (CMRX) came out with a quarterly loss of $0.23 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.21 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.21 per share when it actually produced a loss of $0.25, delivering a surprise of -19.05%. Over the last four quarters, the company has surpassed consensus EPS estimates just once. Chimerix, which belongs to ...